Tuesday 28 July 2009

Formoterol IPS




Formoterol IPS may be available in the countries listed below.


Ingredient matches for Formoterol IPS



Formoterol

Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Formoterol IPS in the following countries:


  • Luxembourg

International Drug Name Search

Docetaxel




In the US, Docetaxel (docetaxel systemic) is a member of the drug class mitotic inhibitors and is used to treat Breast Cancer, Breast Cancer - Metastatic, Gastric Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and Solid Tumors.

US matches:

  • Docetaxel

  • Docetaxel Intravenous

UK matches:

  • Docetaxel Actavis 20mg/0.5ml concentrate and solvent for solution for infusion (SPC)
  • Docetaxel Actavis 20mg/0.5ml Concentrate for Solution for Infusion (SPC)
  • Docetaxel Actavis 80 mg/2 ml concentrate and solvent for solution for infusion (SPC)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01CD02

CAS registry number (Chemical Abstracts Service)

0114977-28-5

Chemical Formula

C43-H53-N-O14

Molecular Weight

807

Therapeutic Category

Antineoplastic agent

Chemical Names

(2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5ß-20-epoxy-1,2α,4,7ß,10ß,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate (WHO)

(2R,3S)-4-acetoxy-2α-benzyloxy-13-[3-(N-tert-butoxycarbonyl)amino-2-hydroxy-3-phenyl]propionyl-5beta,20-epoxy-1,7beta,10beta-trihydroxy-9-oxotax-11-en-13α-ylester (IUPAC)

Foreign Names

  • Docetaxelum (Latin)
  • Docetaxel (German)
  • Docétaxel (French)
  • Docetaxel (Spanish)

Generic Names

  • Docetaxel (OS: BAN)
  • Docétaxel (OS: DCF)
  • Docetaxol (IS)
  • HSDB 6965 (IS)
  • NSC-628503 (IS)
  • RP 56976 (IS: RhônePoulencR)
  • Docetaxel (OS: USAN)

Brand Names

  • Asodocel
    Raffo, Argentina


  • Brexel
    Kalbe, Indonesia


  • Daxotel
    Biogalenic, Venezuela; Dabur, Georgia


  • Docetaxel Biocrom
    Biocrom, Argentina


  • Docetaxel Delta Farma
    Delta Farma, Argentina


  • Docetaxel Rontag
    Rontag, Argentina


  • Docetaxel Sandoz
    Sandoz, Argentina; Sandoz, Colombia


  • Docetaxel Servycal
    Servycal, Argentina


  • Docetaxel Varifarma
    Varifarma, Argentina


  • Docetaxel
    Biocrom, Peru; GP Pharm, Peru; Servycal, Peru


  • Docetere
    Dr Reddys, Sri Lanka; Dr. Reddy's, Peru


  • Dolectran
    LKM, Argentina


  • Donataxel
    Bioprofarma, Argentina


  • Doxetal
    Richmond, Argentina; Richmond, Peru


  • Oncodocel
    Tecnofarma, Colombia; Tecnofarma, Peru


  • Plustaxano
    Dosa, Argentina


  • Tautax
    Verofarm, Russian Federation


  • Taxotere
    Aventis, Bosnia & Herzegowina; Aventis, Ghana; Aventis, Kenya; Aventis, Luxembourg; Aventis, Nigeria; Aventis, Peru; Aventis, Serbia; Aventis, Slovenia; Aventis, Tunisia; Aventis, Uganda; Aventis, Zimbabwe; Aventis Pharma, Norway; Aventis Pharma-F, Italy; Sanofi-Aventis, Australia; Sanofi-Aventis, Bangladesh; Sanofi-Aventis, Canada; Sanofi-Aventis, Denmark; Sanofi-Aventis, Dominican Republic; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Hungary; Sanofi-Aventis, Indonesia; Sanofi-Aventis, Ireland; Sanofi-Aventis, Israel; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Oman; Sanofi-Aventis, Romania; Sanofi-Aventis, Russian Federation; Sanofi-Aventis, Slovakia; Sanofi-Aventis, Thailand; Sanofi-Aventis, Turkey; Sanofi-Aventis, Taiwan; Sanofi-Aventis, Taiwan; Sanofi-Aventis, United States; Sanofi-Aventis, Venezuela; Sanofi-Aventis, Vietnam; Sanofi-Aventis S.A.U., Spain; Sindan, Romania


  • Taxuba
    Glenmark, India


  • Texot
    Filaxis, Argentina


  • Trazoteva
    Teva, Argentina


  • Asodocel
    Asofarma, Argentina


  • Daxotel
    Dabur, India; Dabur, Philippines


  • Docetax
    Cemelog-BRS, Bulgaria


  • Docetaxel Microsules
    Microsules, Argentina


  • Docetere
    Ferron, Indonesia


  • Oncotaxel
    Biotoscana, Colombia


  • Taxotere
    Aventis, Brazil; Aventis, Czech Republic; Aventis, Iceland; Aventis, New Zealand; Aventis, Poland; Aventis, South Africa; Sanofi Aventis, Japan; Sanofi-Aventis, Argentina; Sanofi-Aventis, Austria; Sanofi-Aventis, Belgium; Sanofi-Aventis, Burkina Faso; Sanofi-Aventis, Benin; Sanofi-Aventis, Congo; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Cote D'ivoire; Sanofi-Aventis, Chile; Sanofi-Aventis, Cameroon; Sanofi-Aventis, Colombia; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Germany; Sanofi-Aventis, Dominican Republic; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Finland; Sanofi-Aventis, France; Sanofi-Aventis, Gabon; Sanofi-Aventis, United Kingdom; Sanofi-Aventis, Georgia; Sanofi-Aventis, Guinea; Sanofi-Aventis, Greece; Sanofi-Aventis, Guatemala; Sanofi-Aventis, Honduras; Sanofi-Aventis, Croatia (Hrvatska); Sanofi-Aventis, Mali; Sanofi-Aventis, Mexico; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Panama; Sanofi-Aventis, Sweden; Sanofi-Aventis, Singapore; Sanofi-Aventis, Senegal; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Togo; Sanofi-Aventis, Zaire; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
SPC Summary of Product Characteristics (UK)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Oxa-CT




Oxa-CT may be available in the countries listed below.


Ingredient matches for Oxa-CT



Oxazepam

Oxazepam is reported as an ingredient of Oxa-CT in the following countries:


  • Germany

International Drug Name Search

Monday 27 July 2009

Dolacet


Pronunciation: a-SEET-a-MIN-oh-fen/HYE-droe-KOE-done
Generic Name: Acetaminophen/Hydrocodone
Brand Name: Examples include Dolacet and Stagesic

Dolacet contains acetaminophen. Severe and sometimes fatal liver problems, including the need for liver transplant, have been reported with the use of acetaminophen. Most cases of these liver problems occurred in patients taking excessive doses of acetaminophen (more than 4,000 mg per day). Also, patients who developed these liver problems were often using more than 1 medicine that contained acetaminophen. Discuss any questions or concerns with your doctor.





Dolacet is used for:

Treating moderate to moderately severe pain. It may also be used for other conditions as determined by your doctor.


Dolacet is an analgesic combination. Acetaminophen works by lowering a chemical in the brain that stimulates pain nerves. Hydrocodone, an opioid (narcotic) analgesic, works by binding to receptors in the brain and nervous system used by the body's natural "pain relievers." The combination may provide better pain relief than either medicine alone.


Do NOT use Dolacet if:


  • you are allergic to any ingredient in Dolacet

  • you have diarrhea associated with poisoning, antibiotic use, or a bacterial infection (from eating or drinking contaminated food or water)

  • you are taking sodium oxybate (GHB)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Dolacet:


Some medical conditions may interact with Dolacet. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you are allergic to other narcotic medicines (eg, medicines that contain codeine, morphine, oxycodone)

  • if you have or have ever had alcoholism, substance abuse, narcotic dependence, or if you consume more than 3 alcoholic drinks per day

  • if you have a history of suicidal thoughts or behavior

  • if you have a head injury, increased pressure in the head, a brain injury or tumor, epilepsy, or seizures

  • if you are having an asthma attack

  • if you have an acute stomach or intestinal problem, chronic inflammation and ulceration of the bowel, or you have had recent abdominal surgery

  • if you have adrenal gland problems; enlargement of the prostate gland; heart failure or lung disease, including shortness of breath; liver or kidney problems; thyroid disease; urinary blockage; or viral hepatitis

Some MEDICINES MAY INTERACT with Dolacet. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Barbiturate anesthetics (eg, thiopental), cimetidine, monoamine oxidase inhibitors (MAOIs) (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because serious side effects, such as increased sleepiness and decreased ability to breathe, may occur

  • Naltrexone because it may decrease the effectiveness of Dolacet and withdrawal symptoms may occur in patients who have become physically dependent on opioids

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dolacet may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Dolacet:


Use Dolacet as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Dolacet by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • If you miss a dose of Dolacet, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dolacet.



Important safety information:


  • Dolacet may cause drowsiness, dizziness, blurred vision, or light-headedness. These effects may be worse if you take it with alcohol or certain medicines. Use Dolacet with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Dolacet; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Dolacet may cause dizziness, light-headedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Some of these products contain sulfites. Sulfites may cause an allergic reaction in some patients (eg, asthma patients). If you have ever had an allergic reaction to sulfites, ask your pharmacist if your product has sulfites in it.

  • Dolacet has acetaminophen in it. Before you start any new medicine, check the label to see if it has acetaminophen in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Dolacet may harm your liver. Your risk may be greater if you drink alcohol while you are using Dolacet. Talk to your doctor before you take Dolacet or other fever reducers if you drink more than 3 drinks with alcohol per day.

  • Use Dolacet with caution in the ELDERLY; they may be more sensitive to its effects, especially possible decreased breathing and drowsiness.

  • Dolacet should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dolacet while you are pregnant. Dolacet is found in breast milk. Do not breast-feed while taking Dolacet.

When used for long periods of time or at high doses, Dolacet may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Dolacet stops working well. Do not take more than prescribed.


Some people who use Dolacet for a long time may develop a need to continue taking it. People who take high doses are also at risk. This is known as DEPENDENCE or addiction.


If you suddenly stop taking Dolacet, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; nausea; vomiting; pain; rigid muscles; rapid heartbeat; seeing, hearing, or feeling things that are not there; shivering or tremors; sweating; and trouble sleeping.



Possible side effects of Dolacet:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Blurred vision; constipation; dizziness; drowsiness; flushing; light-headedness; nausea; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); anxiety; change in the amount of urine produced; fear; hearing change or loss; interrupted breathing; mental or mood changes; unusual tiredness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Dolacet side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include bluish skin; cold/clammy skin; difficult or slow breathing; drowsiness leading to unresponsiveness or coma; excessive sweating; loss of function in the heart and lungs; nausea and vomiting; pinpoint pupils; seizure; stomach or intestinal pain.


Proper storage of Dolacet:

Store Dolacet at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not refrigerate. Do not freeze. Dispense in a tight, light-resistant container. Do not store in the bathroom. Keep Dolacet out of the reach of children and away from pets.


General information:


  • If you have any questions about Dolacet, please talk with your doctor, pharmacist, or other health care provider.

  • Dolacet is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dolacet. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dolacet resources


  • Dolacet Side Effects (in more detail)
  • Dolacet Use in Pregnancy & Breastfeeding
  • Dolacet Drug Interactions
  • Dolacet Support Group
  • 0 Reviews for Dolacet - Add your own review/rating


  • Anexsia Advanced Consumer (Micromedex) - Includes Dosage Information

  • Co-gesic Prescribing Information (FDA)

  • Hycet Prescribing Information (FDA)

  • Liquicet Prescribing Information (FDA)

  • Lorcet Plus Prescribing Information (FDA)

  • Lortab Consumer Overview

  • Lortab Prescribing Information (FDA)

  • Maxidone Prescribing Information (FDA)

  • Norco Prescribing Information (FDA)

  • Norco Consumer Overview

  • Vicodin Consumer Overview

  • Vicodin Prescribing Information (FDA)

  • Vicodin ES Prescribing Information (FDA)

  • Vicodin HP Prescribing Information (FDA)

  • Xodol Prescribing Information (FDA)

  • Zolvit Prescribing Information (FDA)

  • Zydone Prescribing Information (FDA)



Compare Dolacet with other medications


  • Back Pain
  • Cough
  • Pain
  • Rheumatoid Arthritis

Isotrex




Isotrex may be available in the countries listed below.


UK matches:

  • Isotrex Gel (Stiefel Laboratories (UK) Limited) (SPC)

Ingredient matches for Isotrex



Isotretinoin

Isotretinoin is reported as an ingredient of Isotrex in the following countries:


  • Argentina

  • Australia

  • Austria

  • Bahrain

  • Chile

  • Colombia

  • Costa Rica

  • Denmark

  • Dominican Republic

  • Egypt

  • El Salvador

  • Germany

  • Guatemala

  • Honduras

  • Hong Kong

  • Hungary

  • Iran

  • Ireland

  • Israel

  • Italy

  • Jordan

  • Kenya

  • Kuwait

  • Lebanon

  • Luxembourg

  • Malta

  • Mexico

  • New Zealand

  • Nicaragua

  • Panama

  • Poland

  • Portugal

  • Qatar

  • Saudi Arabia

  • Singapore

  • Spain

  • Syria

  • Taiwan

  • Tunisia

  • United Arab Emirates

  • United Kingdom

  • Venezuela

  • Yemen

  • Zimbabwe

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday 25 July 2009

Iridus




Iridus may be available in the countries listed below.


Ingredient matches for Iridus



Naftidrofuryl

Naftidrofuryl oxalate (a derivative of Naftidrofuryl) is reported as an ingredient of Iridus in the following countries:


  • Mexico

  • Venezuela

International Drug Name Search

Friday 24 July 2009

Fluconazol-CT




Fluconazol-CT may be available in the countries listed below.


Ingredient matches for Fluconazol-CT



Fluconazole

Fluconazole is reported as an ingredient of Fluconazol-CT in the following countries:


  • Germany

International Drug Name Search

Tuesday 21 July 2009

Rheugesic




Rheugesic may be available in the countries listed below.


Ingredient matches for Rheugesic



Piroxicam

Piroxicam is reported as an ingredient of Rheugesic in the following countries:


  • South Africa

International Drug Name Search

Sunday 19 July 2009

Sertraline EG




Sertraline EG may be available in the countries listed below.


Ingredient matches for Sertraline EG



Sertraline

Sertraline is reported as an ingredient of Sertraline EG in the following countries:


  • Luxembourg

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertraline EG in the following countries:


  • Belgium

  • France

International Drug Name Search

Friday 17 July 2009

Perphénazine




Perphénazine may be available in the countries listed below.


Ingredient matches for Perphénazine



Perphenazine

Perphénazine (DCF) is known as Perphenazine in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday 11 July 2009

Dembrexine




In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0083200-09-3

Chemical Formula

C13-H17-Br2-N-O2

Molecular Weight

379

Therapeutic Category

Mucolytic agent

Chemical Name

Phenol, 2,4-dibromo-6-[[(4-hydroxycyclohexyl)amino]methyl]-, trans-

Foreign Names

  • Dembrexinum (Latin)
  • Dembrexin (German)
  • Dembrexine (French)
  • Dembrexina (Spanish)

Generic Names

  • Dembrexine (OS: BAN)
  • Dembroxol (IS)
  • Dembrexine hydrochloride monohydrate for veterinary use (PH: Ph. Eur. 6)
  • Dembrexini hydrochloridum monohydricum ad usum veterinarium (PH: Ph. Eur. 6)

Brand Names

  • Sputolysin (veterinary use)
    Boehringer Ingelheim, Australia


  • Sputolosin (veterinary use)
    Boehringer Ingelheim Santé Animale, France; Boehringer Ingelheim Vetmedica, United Kingdom; Boehringer Ingelheim Vetmedica, Ireland


  • Sputolysin (veterinary use)
    Boehringer Ingelheim Animal, Netherlands; Boehringer Ingelheim vet, Switzerland; Boehringer Ingelheim vet, Italy; Boehringer Ingelheim Vetmedica, Austria; Boehrvet, Germany; Vetcare, Finland


  • Venti Plus (Dembrexine and Clenbuterol (veterinary use))
    Boehringer Ingelheim vet, Switzerland; Boehringer Ingelheim Vetmedica, Austria; Boehrvet, Germany

International Drug Name Search

Glossary

BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday 7 July 2009

Aerodyl




Aerodyl may be available in the countries listed below.


Ingredient matches for Aerodyl



Bambuterol

Bambuterol hydrochloride (a derivative of Bambuterol) is reported as an ingredient of Aerodyl in the following countries:


  • Bangladesh

International Drug Name Search

Monday 6 July 2009

Evista


Evista is a brand name of raloxifene, approved by the FDA in the following formulation(s):


EVISTA (raloxifene hydrochloride - tablet; oral)



  • Manufacturer: LILLY

    Approval date: December 9, 1997

    Strength(s): 60MG [RLD]

Has a generic version of Evista been approved?


No. There is currently no therapeutically equivalent version of Evista available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evista. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Methods for inhibiting bone loss
    Patent 5,393,763
    Issued: February 28, 1995
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:

    • July 28, 2012
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted




  • Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylime thanone hydrochloride
    Patent 5,457,117
    Issued: October 10, 1995
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)thien-3-yl-4[2-(piperidin-1-ethoxyph enol]methanone hydrochloride.
    Patent expiration dates:

    • July 28, 2012
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted




  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent 5,478,847
    Issued: December 26, 1995
    Inventor(s): Draper; Michael W.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:

    • March 2, 2014
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted




  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,811,120
    Issued: September 22, 1998
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.
    Patent expiration dates:

    • March 2, 2014




  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,972,383
    Issued: October 26, 1999
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.
    Patent expiration dates:

    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF OSTEOPOROSIS




  • Benzothiophenes formulations containing same and methods
    Patent 6,458,811
    Issued: October 1, 2002
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:

    • March 10, 2017
      ✓ 
      Patent use: USE FOR PREVENTION OF BREAST CANCER
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Benzothiophenes, formulations containing same, and methods
    Patent 6,797,719
    Issued: September 28, 2004
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:

    • March 10, 2017
      ✓ 
      Drug product




  • Benzothiophenes, formulations containing same, and methods
    Patent 6,894,064
    Issued: May 17, 2005
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:

    • March 10, 2017
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product




  • Methods for inhibiting bone loss
    Patent 6,906,086
    Issued: June 14, 2005
    Inventor(s): Black; Larry J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:

    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN


    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN




  • Benzothiophenes, formulations containing same, and methods
    Patent 8,030,330
    Issued: October 4, 2011
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:

    • March 10, 2017
      ✓ 
      Drug product




  • Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
    Patent RE38968
    Issued: February 7, 2006
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)-thien-3-yl-4[2-piperidin-1-ethoxyphenol]methanone hydrochloride.
    Patent expiration dates:

    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN


    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN




  • Methods for inhibiting bone loss
    Patent RE39049
    Issued: March 28, 2006
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:

    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN


    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN




  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent RE39050
    Issued: March 28, 2006
    Inventor(s): Draper; Michael W. & Black; Larry J.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompassed by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:

    • March 2, 2014
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN


    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 13, 2010 - REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

    • September 13, 2014 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Evista Consumer Information (Drugs.com)
  • Evista Consumer Information (Wolters Kluwer)
  • Evista Consumer Information (Cerner Multum)
  • Evista Advanced Consumer Information (Micromedex)
  • Evista AHFS DI Monographs (ASHP)
  • Raloxifene Consumer Information (Wolters Kluwer)
  • Raloxifene Consumer Information (Cerner Multum)
  • Raloxifene Advanced Consumer Information (Micromedex)
  • Raloxifene Hydrochloride AHFS DI Monographs (ASHP)